Dogwood Therapeutics: Sealbond acquires 4.1M shares

Conjoint Inc. also directly held 2,842,638 Dogwood common shares through a wholly owned corporate chain ending with CKLS.

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. (DWTX) reported that Sealbond Limited acquired 4,098,360 common shares in a private placement on October 26, 2026, at $1.22 per share, bringing its directly held position to 25,920,693 shares. The shares were acquired under a Subscription Agreement dated October 19, 2026. Conjoint Inc. directly held 2,842,638 shares as of October 26, 2026; it is in a wholly owned chain ending with CK Life Sciences Intl (Holdings) Inc. (CKLS), which disclaimed Section 16 beneficial ownership except to the extent, if any, of its pecuniary interest. Remarks state that Yu Ying Choi Alan Abel, CKLS’s Deputy Chairman, and Toh Kean Meng Melvin, CKLS’s Vice President and Chief Scientific Officer and Executive Director, were appointed to Dogwood’s board and deputized to represent the reporting person. By virtue of their representation, the reporting person may be deemed a director by deputization for Section 16; each individual filed a separate Section 16 report.

Insider Trade Summary

Grant/Award: 4,098,360 shares

Grant/Award 2 txns

Insider Sealbond Ltd, Conjoint Inc., CK Life Sciences Intl (Holdings) Inc

Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	4,098,360	$1.22	$5.00M
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 25,920,693 shares (Direct); Common Stock — 2,842,638 shares (Indirect, By Conjoint Inc.)

Footnotes (3)

1. F1. Shares acquired in a private placement pursuant to a Subscription Agreement dated October 19, 2026 by and between the Issuer and Sealbond Limited.
2. F2. Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
3. F3. Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Key Figures

Common shares acquired: 4,098,360 shares Price per share: $1.22 per share Direct shares following acquisition: 25,920,693 shares +1 more

4 metrics

Common shares acquired 4,098,360 shares Sealbond Limited, October 26, 2026 private placement

Price per share $1.22 per share Sealbond Limited’s October 26, 2026 acquisition

Direct shares following acquisition 25,920,693 shares Sealbond Limited

Conjoint direct holdings 2,842,638 shares As of October 26, 2026

Key Terms

private placement, pecuniary interest, director by deputization

3 terms

private placement financial

"acquired in a private placement pursuant to a Subscription Agreement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pecuniary interest financial

"except to the extent, if any, of its pecuniary interest"

director by deputization regulatory

"may be deemed a director by deputization of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DWTX shares did Sealbond acquire, and at what price?

Sealbond Limited acquired 4,098,360 Dogwood common shares at $1.22 per share on October 26, 2026, in a private placement. The acquisition was made pursuant to a Subscription Agreement dated October 19, 2026.

How is Conjoint Inc. related to CKLS in DWTX’s Form 4?

Conjoint Inc. is a wholly owned subsidiary of Honglad Limited, which is a wholly owned subsidiary of ENSO Resources Limited; ENSO Resources is a wholly owned subsidiary of CKLS. Conjoint directly held 2,842,638 Dogwood common shares as of October 26, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sealbond Ltd

(Last) (First) (Middle)

2 DAI FU STREET,

TAI PO INDUSTRIAL ESTATE

(Street)

NEW TERRITORIES

(City) (State) (Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/26/2026		A(1)		4,098,360	A	$1.22(1)	25,920,693	D(2)
Common Stock								2,842,638	I(3)	By Conjoint Inc.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Sealbond Ltd

(Last) (First) (Middle)

2 DAI FU STREET,

TAI PO INDUSTRIAL ESTATE

(Street)

NEW TERRITORIES

(City) (State) (Zip)

HONG KONG

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Conjoint Inc.

(Last) (First) (Middle)

2 DAI FU STREET,

TAI PO INDUSTRIAL ESTATE

(Street)

NEW TERRITORIES

(City) (State) (Zip)

HONG KONG

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

CK Life Sciences Intl (Holdings) Inc

(Last) (First) (Middle)

2 DAI FU STREET,

TAI PO INDUSTRIAL ESTATE

(Street)

NEW TERRITORIES

(City) (State) (Zip)

HONG KONG

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

Explanation of Responses:

1. Shares acquired in a private placement pursuant to a Subscription Agreement dated October 19, 2026 by and between the Issuer and Sealbond Limited.

2. Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

3. Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Remarks:

Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.

	/s/ Wong Wun Lam, Director of Sealbond Limited	10/27/2026
	/s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc.	10/27/2026
	/s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)